Aurora produces and sells medical cannabis products, including dried flower, oils, vapes, and edibles, to patients and healthcare providers globally. Aurora produces most of its own cannabis through facilities in Canada and Germany that meet international pharmaceutical manufacturing standards. Aurora is exiting the Canadian recreational market to concentrate resources on its medical cannabis business. In Canada, Aurora sells directly to patients through an online marketplace, while in international markets, Aurora distributes through wholesalers and pharmacies. Aurora focuses on the premium and core segments of the market, utilizing a proprietary genetics program to develop high-potency cannabis strains. Aurora holds top market share positions in Canada, Poland, Germany, and Australia. Aurora is expanding production capacity in Germany, acquiring additional certified facilities, and entering emerging markets across Europe to drive growth. Aurora manages its supply chain to ensure consistent product availability, which is critical for patients and prescribers. Aurora relies on maintaining regulatory certifications and physician relationships to drive patient enrollment and product prescriptions.